NCT05468593Completed
Patient Outcomes After Hepatic Artery Infusion Pump Placement
Patient Reported Outcomes After Hepatic Artery Infusion Pump Placement
Source: ClinicalTrials.gov · Last updated 30 Jul 2024
Brief summary (registry, in English)
The purpose of this study is to evaluate the surgical outcomes and the quality of life (QOL) in patients undergoing hepatic artery infusion pump placement for colorectal liver metastases (CRLM).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 12 (actual)
- First submitted
- 12 Jul 2022
- Start date
- 12 Jul 2022
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- Mayo Clinic
- Diseases
- Colorectal cancer
- NCT number
- NCT05468593
What you commit to
- Study type: Observational
- Participants enrolled: 12
- From 12 Jul 2022 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Systemic disease.
Other
- Absence of written consent.
- Pregnancy.
Who the study is looking for
- Patients who receive a Hepatic Artery Infusion Pump at Mayo Clinic Rochester for liver metastases from colorectal cancer.
- Written consent.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic - Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.